Skip to main content
Celltrion, Inc. logo

Celltrion, Inc. — Investor Relations & Filings

Ticker · 068270 ISIN · KR7068270008 LEI · 988400JFZG785WJX3D68 KO Manufacturing
Open in API
Filings indexed 1,279 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 068270

About Celltrion, Inc.

https://www.celltrion.com/

Celltrion, Inc. is a biopharmaceutical company that provides integrated solutions across the entire value chain, from research and development to clinical trials, regulatory affairs, and large-scale manufacturing. The company specializes in developing and producing innovative therapeutics, including biosimilars and novel biopharmaceuticals. Its portfolio primarily targets autoimmune diseases and oncology. Celltrion is recognized for launching the world's first monoclonal antibody biosimilar. A key product is ZYMFENTRA® (infliximab-dyyb), a subcutaneous formulation for the maintenance treatment of moderately-to-severely active Crohn's disease and ulcerative colitis. The company also develops and manufactures chemical pharmaceuticals.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is a Korean ‘분기보고서’ covering the first quarter (2026-01-01 to 2026-03-31) of 주식회사 셀트리온, containing complete interim financial statements, management discussion, auditor’s opinion, and other comprehensive disclosures. This aligns with an Interim/Quarterly Report rather than an earnings release or announcement. Therefore, it should be classified as IR. Q1 2026
2026-05-15 Korean
투자판단관련주요경영사항 (CTP55(코센틱스 바이오시밀러) 미국 임상 3상 시험계획 변경신청 승인 )
Regulatory Filings Classification · 92% confidence The document is a Korean KRX regulatory disclosure titled “투자판단 관련 주요경영사항” that provides details on an FDA approval for a change in the Phase 3 clinical trial plan of a biosimilar. It is an operational/business event announcement and does not contain financial statements, voting results, capital changes, or other specialized content. Therefore, it falls into the general “Regulatory Filings” category as a miscellaneous regulatory announcement.
2026-05-12 Korean
[기재정정]타법인주식및출자증권취득결정
Share Issue/Capital Change Classification · 85% confidence The document is a Korean regulatory disclosure titled “타법인 주식 및 출자증권 취득결정” and a subsequent correction (“정정신고(보고)”), detailing the decision to acquire shares and equity securities in an affiliate company through participation in its capital increase. It is not a financial report (10-K, IR) nor an earnings release or AGM material. It announces the terms of a share acquisition/new share issuance and related capital changes. This matches the “Share Issue/Capital Change” category (Code: SHA).
2026-05-11 Korean
[기재정정]유상증자결정(종속회사의주요경영사항)
Share Issue/Capital Change Classification · 92% confidence The document is a regulatory disclosure detailing the decision to increase capital (“유상증자결정”) for a subsidiary, including share counts, issuance price, subscription schedule, and purpose of proceeds. It is not an AGM material, earnings release, or full financial report, but a notice of a new share issue (capital change). Therefore, it fits the Share Issue/Capital Change category (SHA).
2026-05-11 Korean
자기주식취득결과보고서
Regulatory Filings
2026-05-08 Korean
[기재정정]주식소각결정
Regulatory Filings
2026-05-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.